A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
UVA Human Immune Therapy Center
Oncovir, Inc.
Information provided by (Responsible Party):
University of Virginia
ClinicalTrials.gov Identifier:
NCT01585350
First received: April 24, 2012
Last updated: June 16, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)